Maxwell Biosciences

Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This world-first drug class called Maxwell’s

PeptoidsTM mimics natural human immune system antimicrobial peptides.

Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against Herpes virus and SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” virucidal drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics. Maxwell is raising funds for advanced preclinical and human trials.